Key Highlights
- 1315 Capital leads investment to fuel Experic’s expansion in biopharmaceutical services.
- Investment to enhance manufacturing capabilities and support global growth.
- Experic’s unique expertise in low-dose powder handling and agile services to benefit biopharma industry demands.
Source: Business Wire
Notable Quotes
- “1315 Capital’s investment will empower Experic to continue delivering innovative solutions and white glove services that meet our clients’ needs while expanding our footprint in the global biopharma market.” — David Wood, CEO and Chairman at Experic
- “We are excited to partner with Experic as they continue to expand their capabilities and global reach.” — Matt Reber, Partner at 1315 Capital
SoHC's Take
Experic’s partnership with 1315 Capital marks a strategic growth phase, particularly relevant as biopharma companies increasingly rely on specialized CDMOs to bring innovative therapies to market. This capital boost enables Experic to scale its distinctive offerings, notably in low-dose powder processing and client-focused services, aligning with the broader industry shift toward precision and flexibility in drug manufacturing. The enhanced capabilities and global expansion will position Experic to meet escalating demands within a competitive and fast-evolving biopharma landscape.
